Searchable abstracts of presentations at key conferences in endocrinology

ea0049s2.2 | Evolving diagnostics in adrenal and neuroendocrine tumours | ECE2017

Current status in morphological imaging in adrenal and gastrointestinal neuroendocrine tumours

Anders Sundin

Computed Tomography (CT) constitutes the basic technique for imaging of adrenal tumours and neuroendocrine tumours (NETs). The major work-load in adrenal imaging is characterisation of adrenal incidentalomas, i.e. adrenal tumours diagnosed on imaging performed for other reasons than adrenal disease. Myelolipomas, which have a typical appearance with areas of macroscopic fat, and simple cysts are easy to characterize and require no follow-up. Morphologically benign adrenal tumo...

ea0032s5.2 | A guide through the labyrinth of neuroendocrine tumours | ECE2013

Nuclear medicine imaging of neuroendocrine tumours

Sundin Anders

Computed tomography (CT) is the basic method for morphological imaging of neuroendocrine tumours (NETs) for visualization of local tumour extent and staging of regional and distant metastases. Magnetic resonance imaging (MRI) and intravenously contrast-enhanced ultrasound (CEUS) are complementary methods but are less frequently available and are therefore predominately used when CT does not suffice. This, however, varies depending on the local situation and expertise. Endoscop...

ea0081ep587 | Endocrine-Related Cancer | ECE2022

Poor outcome of systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

Mollazadegan Kazhan , Skogseid Britt , Botling Johan , AEkerstrom Tobias , Eriksson Barbro , Welin Staffan , Anders Sundin , Crona Joakim

Introduction: Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3, that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is currently unknown. Methods: This was a single center retrospective cohort study, aimed to characterize treatment patterns and outcomes among patie...

ea0060p26 | (1) | UKINETS2018

Tumour growth rate (TGR) in neuroendocrine tumours (NETs): changes following systemic treatment and external validation of previous findings; the GREPONET-2 study

Lamarca Angela , Ronot Maxime , Moalla Salma , Crona Joakim , Opalinska Marta , Lopez-Lopez Carlos , Pezzutti Daniela , Najran Pavan , Carvhalo Luciana , Otaviano Franca Bezerra Regis , Borg Philip , Vietti-Violi Naik , Vidal-Trueba Hector , de Mestier Louis , Scaefer Niklaus , Baudin Eric , Sundin Anders , Costa Frederico , Pavel Marianne , Dromain Clarisse

Background: TGR represents the percentage change in tumour volume per month (%/m). Previous results from the GREPONET study (A. Lamarca et al, ENETS 2018) showed that TGR measured after 3 months (TGR3m) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in NETs.Methods: Pts from 7 centres with advanced grade (G) 1/2 NETs from the pancreas (P)/small bowel (SB) initiating ST...